Available online at www.sciencedirect.com

SCIENCE DIRECT®

Schizophrenia Research 81 (2006) 327–330

SCHIZOPHRENIA RESEARCH

www.elsevier.com/locate/schres

Author index to volume 81

Abe, K.A., see Schiffman, J., 253
Angrist, B., see Duncan, E., 323
Annett, M. and Moran, P.
Schizotypy is increased in mixed-handers, especially right-handed writers who use the left hand for primary actions, 239

Balshaw, R., see Kopala, L.C., 29
Baylé, F.J., see Dervaux, A., 151
Bearden, C.E., see O'Brien, M.P., 269
Bediou, B., see Brunelin, J., 41
Bell, M.D. and Mishara, A.L.
Does negative symptom change relate to neurocognitive change in schizophrenia? Implications for targeted treatments, 17
Bitter, I., see Kasper, S., 139
Blanchard, J.J., see Cohen, A.S., 227
Bly, M.
Examination of the zinc transporter gene, SLC39A12, 321
Boesch, J., see Simon, A.E., 83
Bollini, A.M., see Duncan, E., 323
Bourdel, M.-C., see Dervaux, A., 151
Breier, A., see Keefe, R.S.E., 1
Brunelin, J., Poulet, E., Bediou, B., Kallel, L., Dalery, J., D'amato, T. and Saoud, M.
Low frequency repetitive transcranial magnetic stimulation improves source monitoring deficit in hallucinating patients with schizophrenia, 41
Buiteman, C., see Kopala, L.C., 29
Buka, S., see McGrath, J.J., 91
Burdick, K.E., see Thaden, E., 157
Burgess, P.M., see Wade, D., 145
Byerly, M.J., Nakonezny, P.A., Fisher, R., Magouirk, B. and Rush, A.J.
An empirical evaluation of the Arizona sexual experience scale and a simple one-item screening test for assessing antipsychotic-related sexual dysfunction in outpatients with schizophrenia and schizoaffective disorder, 311

Cannon, T.D., see Murray, G.K., 65
Cannon, T.D., see O'Brien, M.P., 269
Cao, L.Y., see Zhang, X.Y., 291
Cervellione, K.L., see Thaden, E., 157
Chan, C.C.H., see Lee, T.M.C., 199
Chan, M.W.C., see Lee, T.M.C., 199
Chan, R.C.K., Chen, E.Y.H., Cheung, E.F.C., Chen, R.Y.L. and Cheung, H.K.
The components of executive functioning in a cohort of patients with chronic schizophrenia: A multiple single-case study design, 173
Chan, Y.-C. and Hankins, M.B.
Clozapine as a short-term antipsychotic medication in patients with schizophrenia, 115
Chen, C.-C., see Lee, H.-C., 283
Chen, E., see Moritz, S., 247
Chen, E.Y.H., see Chan, R.C.K., 173
Chen, E.Y.H., see Lee, T.M.C., 199
Chen, R.Y.L., see Chan, R.C.K., 173
Cheung, E.F.C., see Chan, R.C.K., 173
Cheung, H.K., see Chan, R.C.K., 173
Chronicle, E.P., see Schiffman, J., 253
Cohen, A.S., Forbes, C.B., Mann, M.C. and Blanchard, J.J.
Specific cognitive deficits and differential domains of social functioning impairment in schizophrenia, 227
Cooper, T.B., see Duncan, E., 323
Corcoran, R., see Russell, T.A., 101
Cornblatt, B., see Smith, C.W., 211
Cornblatt, B.A., see Thaden, E., 157

Dalery, J., see Brunelin, J., 41
D'amato, T., see Brunelin, J., 41
Davies, G., see Dolan, M., 277
Dervaux, A., Baylé, F.J., Laqueille, X., Bourdel, M.-C., Leborgne, M., Olié, J.-P. and Krebs, M.-O.
Validity of the CAGE questionnaire in schizophrenic patients with alcohol abuse and dependence, 151
Dolan, M. and Davies, G.
Psychopathy and institutional outcome in patients with schizophrenia in forensic settings in the UK, 277
Doop, M.L. and Park, S.
On knowing and judging smells: Identification and hedonic judgment of odors in schizophrenia, 317
Dossenbach, M., see Kasper, S., 139

0920-9964/$ - see front matter © 2005 Elsevier B.V. All rights reserved.
doi:10.1016/S0920-9964(05)01374-5

Duncan, E., Bollini, A.M., Sanfilipo, M., Wieland, S., Angrist, B., Cooper, T.B. and Rotrosen, J.
Diurnal variation in plasma homovanillic acid in patients with schizophrenia and healthy controls, 323
Dvorsky, D.N., see Simon, A.E., 83

Edwards, J., see Wade, D., 145
Ekstrom, M., see Schiffman, J., 253

Fisher, R., see Byerly, M.J., 311
Forbes, C.B., see Cohen, A.S., 227

Gangadhar, B.N., see Saraswat, N., 301
Gao, J., see Lee, T.M.C., 199
Gilmore, J.H., see Glantz, L.A., 47
Glantz, L.A., Gilmore, J.H., Lieberman, J.A. and Jarskog, L.F.
Apoptotic mechanisms and the synaptic pathology of schizophrenia, 47
Gold, J.M., see Keefe, R.S.E., 1
Good, K.P., see Kopala, L.C., 29
Gordon, J.L., see O'Brien, M.P., 269
Grange, T., see Singh, S.P., 75

Hankins, M.B., see Chan, Y.-C., 115
Harrigan, S., see Wade, D., 145
Hayashi, K., see Schiffman, J., 253
Henderson, I., see Thaden, E., 157
Henriksson, K.M., Larmark, G. and McNeil, T.F.
Smoking in pregnancy and its correlates among women with a history of schizophrenia or affective psychosis, 121
Herba, C., see Russell, T.A., 101
HGGN Study Group, see Keefe, R.S.E., 1
Hodge, A., see Kasper, S., 139
Honer, W.G., see Kopala, L.C., 29

Isler, E., see Simon, A.E., 83
Isohanni, M., see Murray, G.K., 65

Jakary, A., see Théberge, J., 119
Jarskog, L.F., see Glantz, L.A., 47
Jones, P.B., see Murray, G.K., 65
Junghan, U., see Tschacher, W., 261

Kallel, L., see Brunelin, J., 41
Kaneda, Y.
Suicidality in schizophrenia as a separate symptom domain that may be independent of depression or psychosis, 113
Kasper, S., Lowry, A.J., Hodge, A., Bitter, I. and Dossenbach, M.
Tardive dyskinesia: Analysis of outpatients with schizophrenia from Africa and the Middle East, Asia, Central and Eastern Europe, and Latin America, 139
Keefe, R.S.E., Young, C.A., Rock, S.L., Purdon, S.E., Gold, J.M., Breier, A. and HGGN Study Group
One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia, 1
Kester, H., see Thaden, E., 157
Kiss, I., see Kopala, L.C., 29
Kopala, L.C., Good, K.P., Milliken, H., Buiteman, C., Woodley, H., Rui, Q., Whitehorn, D., Love, L., Balshaw, R., Kiss, I. and Honer, W.G.
Treatment of a first episode of psychotic illness with quetiapine: An analysis of 2 year outcomes, 29
Kopelowicz, A., see O'Brien, M.P., 269
Krebs, M.-O., see Dervaux, A., 151
Kumra, S., see Thaden, E., 157
Kurtz, M.M. and Wexler, B.E.
Differences in performance and learning proficiency on the Wisconsin Card Sorting Test in schizophrenia: Do they reflect distinct neurocognitive subtypes with distinct functional profiles?, 167

Laqueille, X., see Dervaux, A., 151
Larmark, G., see Henriksson, K.M., 121
Leborgne, M., see Dervaux, A., 151
Leboyer, M., see Trandafir, A., 217
Lee, H.-C., Tsai, S.-Y., Lin, H.-C. and Chen, C.-C.
The association between psychiatrist numbers and hospitalization costs for schizophrenia patients: A population-based study, 283
Lee, J. and Park, S.
The role of stimulus salience in CPT-AX performance of schizophrenia patients, 191
Lee, T.M.C., Chan, M.W.C., Chan, C.C.H., Gao, J., Wang, K. and Chen, E.Y.H.
Prose memory deficits associated with schizophrenia, 199
Lencz, T., see Thaden, E., 157
Lieberman, D.E., see McGrath, J.J., 91
Lieberman, J.A., see Glantz, L.A., 47
Lin, H.-C., see Lee, H.-C., 283
Lopez, S.R., see O'Brien, M.P., 269
Love, L., see Kopala, L.C., 29
Lowry, A.J., see Kasper, S., 139

Maeda, J.A., see Schiffman, J., 253
Magouirk, B., see Byerly, M.J., 311
Mann, M.C., see Cohen, A.S., 227
McGorry, P.D., see Wade, D., 145
McGrath, J.J., Saha, S., Lieberman, D.E. and Buka, S.
Season of birth is associated with anthropometric and neurocognitive outcomes during infancy and childhood in a general population birth cohort, 91
McNeil, T.F., see Henriksson, K.M., 121
Méary, A., see Trandafir, A., 217
Mednick, S.A., see Schiffman, J., 253
Michelsen, N., see Schiffman, J., 253
Miettunen, J., see Murray, G.K., 65
Milliken, H., see Kopala, L.C., 29
Mishara, A.L., see Bell, M.D., 17
Moilanen, K., see Murray, G.K., 65

Moran, P., see Annett, M., 239
Moritz, S., Woodward, T.S. and Chen, E.
Investigation of metamemory dysfunctions in first-episode schizophrenia, 247
Morris, R., see Russell, T.A., 101
Murray, G.K., Jones, P.B., Moilanen, K., Veijola, J., Miettunen, J., Cannon, T.D. and Isohanni, M.
Infant motor development and adult cognitive functions in schizophrenia, 65

Nakonezny, P.A., see Byerly, M.J., 311
Napolitano, B., see Thaden, E., 157

O'Brien, M.P., Gordon, J.L., Bearden, C.E., Lopez, S.R., Kopelowicz, A. and Cannon, T.D.
Positive family environment predicts improvement in symptoms and social functioning among adolescents at imminent risk for onset of psychosis, 269
Olié, J.-P., see Dervaux, A., 151

Park, S., see Doop, M.L., 317
Park, S., see Lee, J., 191
Park, S., see Smith, C.W., 211
Petralli, C., see Simon, A.E., 83
Pogue-Geile, M.F., see Tarbox, S.I., 125
Poulet, E., see Brunelin, J., 41
Purdon, S.E., see Keefe, R.S.E., 1

Rao, K., see Saraswat, N., 301
Reynaud, E., see Russell, T.A., 101
Rhinewine, J.P., see Thaden, E., 157
Rock, S.L., see Keefe, R.S.E., 1
Roofeh, D., see Thaden, E., 157
Roth, B., see Simon, A.E., 83
Rotrosen, J., see Duncan, E., 323
Rui, Q., see Kopala, L.C., 29
Rush, A.J., see Byerly, M.J., 311
Russell, T.A., Reynaud, E., Herba, C., Morris, R. and Corcoran, R.
Do you see what I see? Interpretations of intentional movement in schizophrenia, 101

Saha, S., see McGrath, J.J., 91
Sanfilipo, M., see Duncan, E., 323
Saoud, M., see Brunelin, J., 41
Saraswat, N., Rao, K., Subbakrishna, D.K. and Gangadhar, B.N.
The Social Occupational Functioning Scale (SOFS): A brief measure of functional status in persons with schizophrenia, 301
Schiffman, J., Maeda, J.A., Hayashi, K., Michelsen, N., Sorensen, H.J., Ekstrom, M., Abe, K.A., Chronicle, E.P. and Mednick, S.A.
Premorbid childhood ocular alignment abnormalities and adult schizophrenia-spectrum disorder, 253
Schueler, P., see Simon, A.E., 83
Schuler, D., see Tschacher, W., 261
Schürhoff, F., see Trandafir, A., 217
Shen, Y., see Zhang, X.Y., 291
Simon, A.E., Dvorsky, D.N., Boesch, J., Roth, B., Isler, E., Schueler, P., Petralli, C. and Umbricht, D.
Defining subjects at risk for psychosis: A comparison of two approaches, 83
Smith, C.W., Park, S. and Cornblatt, B.
Spatial working memory deficits in adolescents at clinical high risk for schizophrenia, 211
Singh, S.P. and Grange, T.
Measuring pathways to care in first-episode psychosis: A systematic review, 75
Sorensen, H.J., see Schiffman, J., 253
Subbakrishna, D.K., see Saraswat, N., 301
Szöke, A., see Trandafir, A., 217

Tan, Y.L., see Zhang, X.Y., 291
Tarbox, S.I. and Pogue-Geile, M.F.
Spontaneous dyskinesia and familial liability to schizophrenia, 125
Thaden, E., Rhinewine, J.P., Lencz, T., Kester, H., Cervellione, K.L., Henderson, I., Roofeh, D., Burdick, K.E., Napolitano, B., Cornblatt, B.A. and Kumra, S.
Early-onset schizophrenia is associated with impaired adolescent development of attentional capacity using the identical pairs continuous performance test, 157
Théberge, J. and Jakary, A.
Comment on "*N*-acetylaspartate reductions in the mediodorsal and anterior thalamus in men with schizophrenia verified by tissue volume corrected proton MRSI" (Schizophr Res 76, 173–185, 2005), 119
Trandafir, A., Méary, A., Schürhoff, F., Leboyer, M. and Szöke, A.
Memory tests in first-degree adult relatives of schizophrenic patients: A meta-analysis, 217
Tsai, S.-Y., see Lee, H.-C., 283
Tschacher, W., Schuler, D. and Junghan, U.
Reduced perception of the motion-induced blindness illusion in schizophrenia, 261

Umbricht, D., see Simon, A.E., 83

Veijola, J., see Murray, G.K., 65

Wade, D., Harrigan, S., Edwards, J., Burgess, P.M., Whelan, G. and McGorry, P.D.
Course of substance misuse and daily tobacco use in first-episode psychosis, 145
Wang, K., see Lee, T.M.C., 199
Wexler, B.E., see Kurtz, M.M., 167
Whelan, G., see Wade, D., 145
Whitehorn, D., see Kopala, L.C., 29
Wieland, S., see Duncan, E., 323

Woodley, H., see Kopala, L.C., 29
Woodward, T.S., see Moritz, S., 247
Wu, G.Y., see Zhang, X.Y., 291

Xu, Q., see Zhang, X.Y., 291

Young, C.A., see Keefe, R.S.E., 1

Zhang, X.Y., Tan, Y.L., Cao, L.Y., Wu, G.Y., Xu, Q., Shen, Y. and Zhou, D.F.
Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics, 291
Zhou, D.F., see Zhang, X.Y., 291

Available online at www.sciencedirect.com

SCIENCE DIRECT®

Schizophrenia Research 81 (2006) 331–336

SCHIZOPHRENIA RESEARCH

www.elsevier.com/locate/schres

Subject index to volume 81

Adolescence
Children; Schizophrenia; Attention; CPT 157

Africa
Schizophrenia; Tardive dyskinesia; Prevalence; Risk factor; Antipsychotic; Asia; Mid-Eastern 139

Alcohol abuse
Schizophrenia; Alcohol dependence 151

Alcohol dependence
Schizophrenia; Alcohol abuse 151

Anthropometry
Seasons; Birth weight; Human development; Vitamin D 91

Antioxidant enzymes
Schizophrenia; Oxidative stress; Lipid peroxidation; Antipsychotics; Psychopathology; Free radicals 291

Antipsychotic
Schizophrenia; Tardive dyskinesia; Prevalence; Risk factor; Africa; Asia; Mid-Eastern 139

Antipsychotics
Neurocognition; Olanzapine; Clinical drug studies; Schizophrenia 1

Antipsychotics
Schizophrenia; Oxidative stress; Antioxidant enzymes; Lipid peroxidation; Psychopathology; Free radicals 291

Antipsychotics
Schizophrenia; Psychosis; Quetiapine; Cognition; Movement disorder; Metabolism 29

Apoptosis
Synapse; Neurite; Schizophrenia; Caspase; Bcl-2 47

ASEX
Schizophrenia; Sexual dysfunction; Rating scale; Screening 311

Asia
Schizophrenia; Tardive dyskinesia; Prevalence; Risk factor; Antipsychotic; Africa; Mid-Eastern 139

At-risk state
Prodrome; Ultra high-risk; Early recognition 83

Attention
Children; Adolescence; Schizophrenia; CPT 157

Attention
Schizophrenia; Working memory; Context; Stimulus-driven attention; Salience 191

Autonoetic agnosia
rTMS; TMS; Source monitoring; Hallucination; Schizophrenia 41

Bcl-2
Apoptosis; Synapse; Neurite; Schizophrenia; Caspase 47

Birth weight
Seasons; Anthropometry; Human development; Vitamin D 91

Caspase
Apoptosis; Synapse; Neurite; Schizophrenia; Bcl-2 47

Children
Adolescence; Schizophrenia; Attention; CPT 157

Clinical drug studies
Antipsychotics; Neurocognition; Olanzapine; Schizophrenia 1

0920-9964/$ - see front matter © 2005 Elsevier B.V. All rights reserved.
doi:10.1016/S0920-9964(05)01375-7

Cognition
Schizophrenia; Psychosis; Quetiapine; Antipsychotics; Movement disorder; Metabolism 29

Cognition
Schizophrenia; Social; Functioning; Community; Symptom 227

Cognitive organization
Motion-induced blindness; Neurocognitive binding; Psychopathology; Schizophrenia spectrum disorder; Stage marker 261

Community
Schizophrenia; Social; Cognition; Functioning; Symptom 227

Context
Schizophrenia; Attention; Working memory; Stimulus-driven attention; Salience 191

Context-memory
Prose memory; Schizophrenia; Verbal memory; Distortions 199

CPT
Children; Adolescence; Schizophrenia; Attention 157

Daily tobacco use
First-episode; Psychosis; Schizophrenia; Substance abuse; Substance dependence 145

Distortions
Prose memory; Schizophrenia; Verbal memory; Context-memory 199

Duration of untreated psychosis
Pathways to care; First-episode psychosis; Schizophrenia; Early intervention in psychosis 75

Early intervention in psychosis
Pathways to care; First-episode psychosis; Schizophrenia; Duration of untreated psychosis 75

Early recognition
Prodrome; At-risk state; Ultra high-risk 83

Endophenotypes
Schizophrenia; Relatives; Memory 217

Executive function
Fractionation; Supervisory attention; Schizophrenia 173

Expressed emotion
Family environment; High-risk youth; Prodrome 269

Factor analysis
Schizophrenia; Social Functioning Scale 301

Family environment
Expressed emotion; High-risk youth; Prodrome 269

First-episode
Psychosis; Schizophrenia; Substance abuse; Substance dependence; Daily tobacco use 145

First-episode psychosis
Pathways to care; Schizophrenia; Duration of untreated psychosis; Early intervention in psychosis 75

Fractionation
Executive function; Supervisory attention; Schizophrenia 173

Free radicals
Schizophrenia; Oxidative stress; Antioxidant enzymes; Lipid peroxidation; Antipsychotics; Psychopathology 291

Functioning
Schizophrenia; Social; Cognition; Community; Symptom 227

Genetics
Schizophrenia; Spontaneous dyskinesia; Movement; Liability; Relatives 125

Hallucination
rTMS; TMS; Source monitoring; Schizophrenia; Autonoetic agnosia 41

Handedness
Schizotypy; O-LIFE inventory; Rust Inventory of Schizotypal Cognitions 239

High-risk adolescence
Schizophrenia; Prodrome; Working memory; Prefrontal function 211

High-risk youth
Family environment; Expressed emotion; Prodrome 269

Human development
Seasons; Birth weight; Anthropometry; Vitamin D 91

Inpatient psychiatry
Schizophrenia; Outcome studies 283

Institutional outcome
Schizophrenia; Psychopathy 277

Learning
Schizophrenia; Wisconsin Card Sorting Test; Rehabilitation 167

Liability
Schizophrenia; Spontaneous dyskinesia; Movement; Genetics; Relatives 125

Lipid peroxidation
Schizophrenia; Oxidative stress; Antioxidant enzymes; Antipsychotics; Psychopathology; Free radicals 291

Longitudinal birth cohort study
Schizophrenia; Neurodevelopment; Neurocognition; Motor development; Neuropsychology 65

Longitudinal relationship
Schizophrenia; Negative symptoms; Neuropsychological tests; Theory of mind 17

Memory
Schizophrenia; Relatives; Endophenotypes 217

Metabolism
Schizophrenia; Psychosis; Quetiapine; Antipsychotics; Cognition; Movement disorder 29

Mid-Eastern
Schizophrenia; Tardive dyskinesia; Prevalence; Risk factor; Antipsychotic; Africa; Asia 139

Motion-induced blindness
Cognitive organization; Neurocognitive binding; Psychopathology; Schizophrenia spectrum disorder; Stage marker 261

Motor development
Schizophrenia; Neurodevelopment; Neurocognition; Neuropsychology; Longitudinal birth cohort study 65

Movement disorder
Schizophrenia; Psychosis; Quetiapine; Antipsychotics; Cognition; Metabolism 29

Movement
Schizophrenia; Spontaneous dyskinesia; Liability; Genetics; Relatives 125

Negative symptoms
Schizophrenia; Neuropsychological tests; Longitudinal relationship; Theory of mind 17

Neurite
Apoptosis; Synapse; Schizophrenia; Caspase; Bcl-2 47

Neurocognition
Antipsychotics; Olanzapine; Clinical drug studies; Schizophrenia 1

Neurocognition
Schizophrenia; Neurodevelopment; Motor development; Neuropsychology; Longitudinal birth cohort study 65

Neurocognitive binding
Cognitive organization; Motion-induced blindness; Psychopathology; Schizophrenia spectrum disorder; Stage marker 261

Neurodevelopment
Schizophrenia; Neurocognition; Motor development; Neuropsychology; Longitudinal birth cohort study 65

Neuropsychological tests
Schizophrenia; Negative symptoms; Longitudinal relationship; Theory of mind 17

Neuropsychology
Schizophrenia; Neurodevelopment; Neurocognition; Motor development; Longitudinal birth cohort study 65

Ocular deficits
Schizophrenia-spectrum; Strabismus; Premorbid; Prospective 253

Olanzapine
Antipsychotics; Neurocognition; Clinical drug studies; Schizophrenia 1

O-LIFE inventory
Schizotypy; Handedness; Rust Inventory of Schizotypal Cognitions 239

On-line mentalising
Theory of mind; Social cognition 101

Outcome studies
Schizophrenia; Inpatient psychiatry 283

Oxidative stress
Schizophrenia; Antioxidant enzymes; Lipid peroxidation; Antipsychotics; Psychopathology; Free radicals 291

Pathways to care
First-episode psychosis; Schizophrenia; Duration of untreated psychosis; Early intervention in psychosis 75

Prefrontal function
Schizophrenia; Prodrome; High-risk adolescence; Working memory 211

Premorbid
Schizophrenia-spectrum; Ocular deficits; Strabismus; Prospective 253

Prevalence
Schizophrenia; Tardive dyskinesia; Risk factor; Antipsychotic; Africa; Asia; Mid-Eastern 139

Prodrome
At-risk state; Ultra high-risk; Early recognition 83

Prodrome
Family environment; Expressed emotion; High-risk youth 269

Prodrome
Schizophrenia; High-risk adolescence; Working memory; Prefrontal function 211

Prose memory
Schizophrenia; Verbal memory; Context-memory; Distortions 199

Prospective
Schizophrenia-spectrum; Ocular deficits; Strabismus; Premorbid 253

Psychopathology
Cognitive organization; Motion-induced blindness; Neurocognitive binding; Schizophrenia spectrum disorder; Stage marker 261

Psychopathology
Schizophrenia; Oxidative stress; Antioxidant enzymes; Lipid peroxidation; Antipsychotics; Free radicals 291

Psychopathy
Schizophrenia; Institutional outcome 277

Psychosis
First-episode; Schizophrenia; Substance abuse; Substance dependence; Daily tobacco use 145

Psychosis
Schizophrenia; Quetiapine; Antipsychotics; Cognition; Movement disorder; Metabolism 29

Quetiapine
Schizophrenia; Psychosis; Antipsychotics; Cognition; Movement disorder; Metabolism 29

Rating scale
Schizophrenia; Sexual dysfunction; Screening; ASEX 311

Rehabilitation
Schizophrenia; Wisconsin Card Sorting Test; Learning 167

Relatives
Schizophrenia; Spontaneous dyskinesia; Movement; Liability; Genetics 125

Relatives
Schizophrenia; Memory; Endophenotypes 217

Risk factor
Schizophrenia; Tardive dyskinesia; Prevalence; Antipsychotic; Africa; Asia; Mid-Eastern 139

rTMS
TMS; Source monitoring; Hallucination; Schizophrenia; Autonoetic agnosia 41

Rust Inventory of Schizotypal Cognitions
Schizotypy; Handedness; O-LIFE inventory 239

Salience
Schizophrenia; Attention; Working memory; Context; Stimulus-driven attention 191

Schizophrenia
Antipsychotics; Neurocognition; Olanzapine; Clinical drug studies 1

Schizophrenia
Negative symptoms; Neuropsychological tests; Longitudinal relationship; Theory of mind 17

Schizophrenia
Psychosis; Quetiapine; Antipsychotics; Cognition; Movement disorder; Metabolism 29

Schizophrenia
rTMS; TMS; Source monitoring; Hallucination; Autonoetic agnosia 41

Schizophrenia
Apoptosis; Synapse; Neurite; Caspase; Bcl-2 47

Schizophrenia
Neurodevelopment; Neurocognition; Motor development; Neuropsychology; Longitudinal birth cohort study 65

Schizophrenia
Pathways to care; First-episode psychosis; Duration of untreated psychosis; Early intervention in psychosis 75

Schizophrenia
Spontaneous dyskinesia; Movement; Liability; Genetics; Relatives 125

Schizophrenia
Tardive dyskinesia; Prevalence; Risk factor; Antipsychotic; Africa; Asia; Mid-Eastern 139

Schizophrenia
First-episode; Psychosis; Substance abuse; Substance dependence; Daily tobacco use 145

Schizophrenia
Alcohol abuse; Alcohol dependence 151

Schizophrenia
Children; Adolescence; Attention; CPT 157

Schizophrenia
Wisconsin Card Sorting Test; Learning; Rehabilitation 167

Schizophrenia
Executive function; Fractionation; Supervisory attention 173

Schizophrenia
Attention; Working memory; Context; Stimulus-driven attention; Salience 191

Schizophrenia
Prose memory; Verbal memory; Context-memory; Distortions 199

Schizophrenia
Prodrome; High-risk adolescence; Working memory; Prefrontal function 211

Schizophrenia
Relatives; Memory; Endophenotypes 217

Schizophrenia
Social; Cognition; Functioning; Community; Symptom 227

Schizophrenia
Psychopathy; Institutional outcome 277

Schizophrenia
Inpatient psychiatry; Outcome studies 283

Schizophrenia
Oxidative stress; Antioxidant enzymes; Lipid peroxidation; Antipsychotics; Psychopathology; Free radicals 291

Schizophrenia
Social Functioning Scale; Factor analysis 301

Schizophrenia
Sexual dysfunction; Rating scale; Screening; ASEX 311

Schizophrenia spectrum disorder
Cognitive organization; Motion-induced blindness; Neurocognitive binding; Psychopathology; Stage marker 261

Schizophrenia-spectrum
Ocular deficits; Strabismus; Premorbid; Prospective 253

Schizotypy
Handedness; O-LIFE inventory; Rust Inventory of Schizotypal Cognitions 239

Screening
Schizophrenia; Sexual dysfunction; Rating scale; ASEX 311

Seasons
Birth weight; Anthropometry; Human development; Vitamin D 91

Sexual dysfunction
Schizophrenia; Rating scale; Screening; ASEX 311

Social cognition
Theory of mind; On-line mentalising 101

Social Functioning Scale
Schizophrenia; Factor analysis 301

Social
Schizophrenia; Cognition; Functioning; Community; Symptom 227

Source monitoring
rTMS; TMS; Hallucination; Schizophrenia; Autonoetic agnosia 41

Spontaneous dyskinesia
Schizophrenia; Movement; Liability; Genetics; Relatives 125

Stage marker
Cognitive organization; Motion-induced blindness; Neurocognitive binding; Psychopathology; Schizophrenia spectrum disorder 261

Stimulus-driven attention
Schizophrenia; Attention; Working memory; Context; Salience 191

Strabismus
Schizophrenia-spectrum; Ocular deficits; Premorbid; Prospective 253

Substance abuse
First-episode; Psychosis; Schizophrenia; Substance dependence; Daily tobacco use 145

Substance dependence
First-episode; Psychosis; Schizophrenia; Substance abuse; Daily tobacco use 145

Supervisory attention
Executive function; Fractionation; Schizophrenia 173

Symptom
Schizophrenia; Social; Cognition; Functioning; Community 227

Synapse
Apoptosis; Neurite; Schizophrenia; Caspase; Bcl-2 47

Tardive dyskinesia
Schizophrenia; Prevalence; Risk factor; Antipsychotic; Africa; Asia; Mid-Eastern 139

Theory of mind
Schizophrenia; Negative symptoms; Neuropsychological tests; Longitudinal relationship 17

Theory of mind
Social cognition; On-line mentalising 101

TMS
rTMS; Source monitoring; Hallucination; Schizophrenia; Autonoetic agnosia 41

Ultra high-risk
Prodrome; At-risk state; Early recognition 83

Verbal memory
Prose memory; Schizophrenia; Context-memory; Distortions 199

Vitamin D
Seasons; Birth weight; Anthropometry; Human development 91

Wisconsin Card Sorting Test
Schizophrenia; Learning; Rehabilitation 167

Working memory
Schizophrenia; Attention; Context; Stimulus-driven attention; Salience 191

Working memory
Schizophrenia; Prodrome; High-risk adolescence; Prefrontal function 211